

# BOOSTRIX<sup>®</sup>

**Tetanus Toxoid, Reduced Diphtheria Toxoid  
and Acellular Pertussis Vaccine, Adsorbed**




**Now indicated for patients aged 10 to 64**

BOOSTRIX is indicated for active booster immunization against tetanus, diphtheria, and pertussis as a single dose in individuals 10 through 64 years of age.

## Protection for adolescents is now available for adults

CDC\* recommends that adults aged 19 to 64 receive a single dose of Tdap to replace Td if they received their last Td  $\geq 10$  years earlier and if they have not previously received Tdap.<sup>1</sup>



### **BOOSTRIX provides:**

#### **Pertussis protection**

- In both adolescents and adults, one dose of BOOSTRIX produced pertussis antibody concentrations that were consistent with pertussis protection<sup>2</sup>
  - There are no generally accepted correlates of protection for pertussis. Licensure of BOOSTRIX was based on immune responses to the vaccine and bridging to clinical efficacy data.

#### **Uncompromised Td immunogenicity**

- Immunogenicity against tetanus and diphtheria (Td) comparable to a US-licensed Td booster in adolescents, and a US-licensed Tdap booster in adults<sup>2,3</sup>

#### **Proven safety profile**

- Can be coadministered with influenza vaccine<sup>†</sup> in adults<sup>2</sup>

## Help protect your patients against pertussis with a single dose of BOOSTRIX

\* Centers for Disease Control and Prevention.

† Fluarix<sup>®</sup> (Influenza Virus Vaccine).

**Please see accompanying complete Prescribing Information and Important Safety Information on reverse side.**

**Established CPT<sup>®</sup> Code: 90715**

# BOOSTRIX<sup>®</sup>

**Tetanus Toxoid, Reduced Diphtheria Toxoid  
and Acellular Pertussis Vaccine, Adsorbed**

**Now indicated for patients  
aged 10 to 64**

## Protection for adolescents is now available for adults

### Easy ordering with no changes to existing codes

- Order BOOSTRIX for adolescents and adults through [gskvaccinesdirect.com](http://gskvaccinesdirect.com) and your approved physician supply house
  - Single-dose vials: NDC 58160-842-11 (10ct)
  - Single-dose Tip-Lok<sup>®</sup> syringes: NDC 58160-842-46 (5ct)
  - CPT<sup>®</sup> Code: 90715
- Available in **Tip-Lok** prefilled, pre-labeled, color-coded syringes—**at no additional cost compared with vials**



BOOSTRIX is indicated for active booster immunization against tetanus, diphtheria, and pertussis as a single dose in individuals 10 through 64 years of age.

### Important Safety Information

- In clinical studies, common adverse events were injection-site reactions (pain, redness, swelling, or increase in arm circumference), headache, fatigue, and gastrointestinal symptoms.
- Severe allergic reaction after a previous dose of BOOSTRIX or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication.
- The decision to give BOOSTRIX should be based on benefits and risks if Guillain-Barré syndrome occurs within 6 weeks of receipt of a prior tetanus toxoid-containing vaccine, or if progressive or unstable neurologic disorders exist.
- Persons who experienced an Arthus-type hypersensitivity reaction following a previous dose of tetanus toxoid-containing vaccine should not receive BOOSTRIX unless 10 years have elapsed.
- The prefilled syringes contain dry natural latex rubber that may cause allergic reactions.

## Please see accompanying complete Prescribing Information.

**References:** 1. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and Recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for Use of Tdap Among Health-Care Personnel. *MMWR*. 2006;55(RR17):1-37. 2. Prescribing Information for BOOSTRIX. 3. Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. *Pediatrics*. 2006;117(4):1084-1093.

BOOSTRIX<sup>®</sup>, FLUARIX<sup>®</sup> and Tip-Lok are registered trademarks, and GSKVaccinesDirect.com is a trademark of GlaxoSmithKline.

CPT is a registered trademark of the American Medical Association.

\* Manufactured by **GlaxoSmithKline Biologicals**, Rixensart, Belgium

† Manufactured by **GlaxoSmithKline Biologicals**, Dresden, Germany

\*Distributed by **GlaxoSmithKline**, Research Triangle Park, NC 27709

©2008 The GlaxoSmithKline Group of Companies All rights reserved. Printed in USA. BRX317RO December 2008



[www.BOOSTRIX.com](http://www.BOOSTRIX.com)